膵臓腺がん治療の世界市場レポート 2025年

膵臓腺がん治療市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR13.3％で39億9,000万米ドルに成長します。予測期間中の成長は、標的治療や免疫療法の拡大、精密医療の採用の増加、バイオマーカーに基づく診断の進歩、ヘルスケア支出の増加、新規治療の臨床試験件数の増加などが要因として考えられます。主な動向としては、AIによる創薬の開発、標的ドラッグデリバリーのためのナノメディシンの拡大、早期発見のためのリキッドバイオプシーの採用、CRISPRベースの遺伝子治療の進歩、治療モニタリングのための遠隔医療の統合などが挙げられます。

消化器系がんの有病率の上昇は、膵臓腺がん治療市場の成長を牽引すると予想されます。これらのがんは、胃、肝臓、膵臓、腸、食道、結腸など消化に関わる臓器で開発されます。このような悪性腫瘍の発生率の増加は、食生活の乱れ、飲酒、喫煙などの不健康なライフスタイルの選択に起因するところが大きいです。膵臓腺がん治療は、消化器系で最も侵攻性の高いがんの一つである消化器がんの管理において、生存率の向上と患者のQOLの向上を目標に、重要な役割を果たしています。例えば、米国の非営利団体である米国がん協会は、2023年1月に米国で6万4,050人が膵臓がんと診断され、5万550人が膵臓がんで死亡すると推定しています。その結果、消化器系がんの発生率の増加が膵臓腺がん治療市場の拡大に寄与しています。

膵臓腺がん治療市場の主要企業は、治療効果を高め、副作用を最小限に抑え、腫瘍抵抗性の課題に対処するため、イリノテカンリポソーム注射剤などの革新的な治療法の開発を優先しています。イリノテカンリポソーム注射液はリポソームに封入された化学療法薬で、がん細胞へのドラッグデリバリーを改善し、効果を高め、膵臓腺がんの治療における副作用を軽減するように設計されています。例えば、2024年2月、フランスのバイオ医薬品会社Ipsen SAは、米国食品医薬品局（FDA）がオキサリプラチンとの併用によるオニバイド（イリノテカンリポソーム注射剤）の新薬追加申請を承認したと発表しました。この併用療法は、従来の治療法に比べて副作用を最小限に抑えながらドラッグデリバリーを改善することにより、腫瘍の標的性を高めるものです。リポソーム製剤はイリノテカンの生物学的利用能と徐放性を高め、オキサリプラチンは膵がん細胞に対する有効性をさらに高める。今回の承認は、この侵攻性のがんに対するより効果的な治療選択肢の必要性を満たすレジメンの可能性を強調するものです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界膵臓腺がん治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の膵臓腺がん治療市場：成長率分析
• 世界の膵臓腺がん治療市場の実績：規模と成長, 2019-2024
• 世界の膵臓腺がん治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界膵臓腺がん治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の膵臓腺がん治療市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 化学療法
• 標的療法
• その他のタイプ
• 世界の膵臓腺がん治療市場被災地別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 外分泌
• 内分泌
• 世界の膵臓腺がん治療市場：チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• その他のチャンネル
• 世界の膵臓腺がん治療市場化学療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 単剤療法
• 併用療法
• 世界の膵臓腺がん治療市場標的療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 低分子阻害剤
• モノクローナル抗体
• 世界の膵臓腺がん治療市場、その他のタイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 免疫療法
• 放射線治療

第7章 地域別・国別分析

• 世界の膵臓腺がん治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の膵臓腺がん治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 膵臓腺がん治療市場：競合情勢
• 膵臓腺がん治療市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• AstraZeneca plc
• Novartis AG
• GlaxoSmithKline plc
• Takeda Pharmaceutical Company Limited（Japan）
• Eli Lilly and Company
• Amgen Inc.
• Teva Pharmaceutical Industries Ltd
• Mylan N.V.
• Astellas Pharma Inc.
• Sun Pharmaceutical Industries Ltd.
• Ipsen SA
• Clovis Oncology Inc.
• Oncolytics Biotech, Inc.
• Zydus Cadila
• PharmaCyte Biotech Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 膵臓腺がん治療市場2029：新たな機会を提供する国
• 膵臓腺がん治療市場2029：新たな機会を提供するセグメント
• 膵臓腺がん治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Pancreatic adenocarcinoma treatment encompasses various medical strategies aimed at managing and combating pancreatic adenocarcinoma, the most common form of pancreatic cancer. Treatment approaches depend on factors such as cancer stage, tumor location, and patient health, typically involving a combination of surgery, chemotherapy, radiation therapy, and targeted therapies to enhance survival and quality of life.

The primary types of pancreatic adenocarcinoma treatment include chemotherapy, targeted therapy, and other modalities. Chemotherapy utilizes drugs to destroy or inhibit the growth of cancer cells and may be employed to shrink tumors before surgery, prevent recurrence post-surgery, or manage advanced stages by alleviating symptoms. The disease primarily affects the exocrine and endocrine regions of the pancreas. Treatment distribution occurs through various channels, including hospital pharmacies, retail pharmacies, and other healthcare providers.

The pancreatic adenocarcinoma treatment market research report is one of a series of new reports from The Business Research Company that provides pancreatic adenocarcinoma treatment market statistics, including pancreatic adenocarcinoma treatment industry global market size, regional shares, competitors with a pancreatic adenocarcinoma treatment market share, detailed pancreatic adenocarcinoma treatment market segments, market trends and opportunities, and any further data you may need to thrive in the pancreatic adenocarcinoma treatment industry. This pancreatic adenocarcinoma treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The pancreatic adenocarcinoma treatment market size has grown rapidly in recent years. It will grow from $2.13 billion in 2024 to $2.42 billion in 2025 at a compound annual growth rate (CAGR) of 13.6%. The growth during the historic period can be attributed to the rising incidence of pancreatic cancer, advancements in chemotherapy and radiation therapy, increased awareness and early diagnosis, regulatory approvals of new treatments, and growing investment in oncology research.

The pancreatic adenocarcinoma treatment market size is expected to see rapid growth in the next few years. It will grow to $3.99 billion in 2029 at a compound annual growth rate (CAGR) of 13.3%. The growth during the forecast period can be driven by the expansion of targeted and immunotherapy treatments, increasing adoption of precision medicine, advancements in biomarker-based diagnostics, rising healthcare expenditure, and a growing number of clinical trials for novel therapies. Major trends include the development of AI-driven drug discovery, expansion of nanomedicine for targeted drug delivery, adoption of liquid biopsy for early detection, advancements in CRISPR-based gene therapy, and the integration of telemedicine for treatment monitoring.

The rising prevalence of digestive system cancers is expected to drive the growth of the pancreatic adenocarcinoma treatment market. These cancers develop in organs involved in digestion, including the stomach, liver, pancreas, intestines, esophagus, and colon. The increasing incidence of such malignancies is largely attributed to unhealthy lifestyle choices such as poor diet, alcohol consumption, and smoking. Pancreatic adenocarcinoma treatment plays a vital role in managing one of the most aggressive cancers of the digestive system, with the goal of improving survival rates and enhancing patients' quality of life. For example, in January 2023, the American Cancer Society, a US-based non-profit organization, estimated that 64,050 individuals in the United States would be diagnosed with pancreatic cancer, while 50,550 were expected to succumb to the disease. As a result, the growing incidence of digestive system cancers is contributing to the expansion of the pancreatic adenocarcinoma treatment market.

Leading companies in the pancreatic adenocarcinoma treatment market are prioritizing the development of innovative therapies, such as irinotecan liposome injection, to enhance treatment efficacy, minimize side effects, and address tumor resistance challenges. Irinotecan liposome injection is a chemotherapy drug encapsulated in liposomes, designed to improve drug delivery to cancer cells, increase effectiveness, and reduce adverse effects in the treatment of pancreatic adenocarcinoma. For instance, in February 2024, Ipsen SA, a France-based biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved the supplemental new drug application for Onivyde (irinotecan liposome injection) in combination with oxaliplatin. This combination enhances tumor targeting by improving drug delivery while minimizing side effects compared to conventional therapies. The liposomal formulation increases the bioavailability and sustained release of irinotecan, while oxaliplatin provides additional efficacy against pancreatic cancer cells. The approval highlights the regimen's potential to fulfill the need for more effective treatment options for this aggressive cancer.

In February 2022, Panbela Therapeutics Inc., a US-based biopharmaceutical company, acquired Cancer Prevention Pharmaceuticals Inc. for an undisclosed amount. This acquisition allows Panbela to expand its oncology pipeline by incorporating the clinical-stage assets of both companies, including SBP-101, which has shown promise in improving overall survival and response rates in metastatic pancreatic adenocarcinoma patients. This development aims to enhance treatment options for this highly aggressive cancer. Cancer Prevention Pharmaceuticals Inc. is a US-based biotechnology company specializing in innovative therapeutics designed to lower cancer risk and recurrence, with a particular focus on familial adenomatous polyposis (FAP), colorectal cancer prevention, and other rare diseases.

Major players in the pancreatic adenocarcinoma treatment market are Pfizer Inc., Roche AG, Merck & Co Inc., Sanofi, Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited (Japan), Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd, Mylan N.V., Astellas Pharma Inc., Sun Pharmaceutical Industries Ltd., Ipsen SA, Clovis Oncology Inc., Oncolytics Biotech Inc., Zydus Cadila, PharmaCyte Biotech Inc., and Infinity Pharmaceuticals Inc.

North America was the largest region in the pancreatic adenocarcinoma treatment market in 2024. The regions covered in pancreatic adenocarcinoma treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the pancreatic adenocarcinoma treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The pancreatic adenocarcinoma treatment market includes revenues earned by entities by providing services such as chemotherapy administration, radiation therapy, surgical procedures, targeted therapy, immunotherapy, supportive care services, and diagnostic testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The pancreatic adenocarcinoma treatment market also includes sales of chemotherapeutic drugs, targeted therapy drugs, immunotherapy agents, radiation therapy equipment, surgical instruments, diagnostic tools, and supportive care medications. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Pancreatic Adenocarcinoma Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pancreatic adenocarcinoma treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for pancreatic adenocarcinoma treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The pancreatic adenocarcinoma treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Chemotherapy, Targeted Therapy, Other Types
• 2) By Affected Area: Exocrine, Endocrine
• 3) By Channel: Hospital Pharmacies, Retail Pharmacies, Other Channels
• Subsegments:
• 1) By Chemotherapy: Monotherapy; Combination Therapy
• 2) By Targeted Therapy: Small Molecule Inhibitors; Monoclonal Antibodies
• 3) By Other Types: Immunotherapy; Radiation Therapy
• Companies Mentioned:Pfizer Inc.; Roche AG; Merck & Co Inc.; Sanofi; Bristol-Myers Squibb Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Pancreatic Adenocarcinoma Treatment Market Characteristics

3. Pancreatic Adenocarcinoma Treatment Market Trends And Strategies

4. Pancreatic Adenocarcinoma Treatment Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Pancreatic Adenocarcinoma Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Pancreatic Adenocarcinoma Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Pancreatic Adenocarcinoma Treatment Market Growth Rate Analysis
• 5.4. Global Pancreatic Adenocarcinoma Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Pancreatic Adenocarcinoma Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Pancreatic Adenocarcinoma Treatment Total Addressable Market (TAM)

6. Pancreatic Adenocarcinoma Treatment Market Segmentation

• 6.1. Global Pancreatic Adenocarcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy
• Targeted Therapy
• Other Types
• 6.2. Global Pancreatic Adenocarcinoma Treatment Market, Segmentation By Affected Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Exocrine
• Endocrine
• 6.3. Global Pancreatic Adenocarcinoma Treatment Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Other Channels
• 6.4. Global Pancreatic Adenocarcinoma Treatment Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monotherapy
• Combination Therapy
• 6.5. Global Pancreatic Adenocarcinoma Treatment Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Small Molecule Inhibitors
• Monoclonal Antibodies
• 6.6. Global Pancreatic Adenocarcinoma Treatment Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immunotherapy
• Radiation Therapy

7. Pancreatic Adenocarcinoma Treatment Market Regional And Country Analysis

• 7.1. Global Pancreatic Adenocarcinoma Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Pancreatic Adenocarcinoma Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Pancreatic Adenocarcinoma Treatment Market

• 8.1. Asia-Pacific Pancreatic Adenocarcinoma Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Pancreatic Adenocarcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Pancreatic Adenocarcinoma Treatment Market, Segmentation By Affected Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Pancreatic Adenocarcinoma Treatment Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Pancreatic Adenocarcinoma Treatment Market

• 9.1. China Pancreatic Adenocarcinoma Treatment Market Overview
• 9.2. China Pancreatic Adenocarcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Pancreatic Adenocarcinoma Treatment Market, Segmentation By Affected Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Pancreatic Adenocarcinoma Treatment Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Pancreatic Adenocarcinoma Treatment Market

• 10.1. India Pancreatic Adenocarcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Pancreatic Adenocarcinoma Treatment Market, Segmentation By Affected Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Pancreatic Adenocarcinoma Treatment Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Pancreatic Adenocarcinoma Treatment Market

• 11.1. Japan Pancreatic Adenocarcinoma Treatment Market Overview
• 11.2. Japan Pancreatic Adenocarcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Pancreatic Adenocarcinoma Treatment Market, Segmentation By Affected Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Pancreatic Adenocarcinoma Treatment Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Pancreatic Adenocarcinoma Treatment Market

• 12.1. Australia Pancreatic Adenocarcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Pancreatic Adenocarcinoma Treatment Market, Segmentation By Affected Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Pancreatic Adenocarcinoma Treatment Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Pancreatic Adenocarcinoma Treatment Market

• 13.1. Indonesia Pancreatic Adenocarcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Pancreatic Adenocarcinoma Treatment Market, Segmentation By Affected Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Pancreatic Adenocarcinoma Treatment Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Pancreatic Adenocarcinoma Treatment Market

• 14.1. South Korea Pancreatic Adenocarcinoma Treatment Market Overview
• 14.2. South Korea Pancreatic Adenocarcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Pancreatic Adenocarcinoma Treatment Market, Segmentation By Affected Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Pancreatic Adenocarcinoma Treatment Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Pancreatic Adenocarcinoma Treatment Market

• 15.1. Western Europe Pancreatic Adenocarcinoma Treatment Market Overview
• 15.2. Western Europe Pancreatic Adenocarcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Pancreatic Adenocarcinoma Treatment Market, Segmentation By Affected Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Pancreatic Adenocarcinoma Treatment Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Pancreatic Adenocarcinoma Treatment Market

• 16.1. UK Pancreatic Adenocarcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Pancreatic Adenocarcinoma Treatment Market, Segmentation By Affected Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Pancreatic Adenocarcinoma Treatment Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Pancreatic Adenocarcinoma Treatment Market

• 17.1. Germany Pancreatic Adenocarcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Pancreatic Adenocarcinoma Treatment Market, Segmentation By Affected Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Pancreatic Adenocarcinoma Treatment Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Pancreatic Adenocarcinoma Treatment Market

• 18.1. France Pancreatic Adenocarcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Pancreatic Adenocarcinoma Treatment Market, Segmentation By Affected Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Pancreatic Adenocarcinoma Treatment Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Pancreatic Adenocarcinoma Treatment Market

• 19.1. Italy Pancreatic Adenocarcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Pancreatic Adenocarcinoma Treatment Market, Segmentation By Affected Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Pancreatic Adenocarcinoma Treatment Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Pancreatic Adenocarcinoma Treatment Market

• 20.1. Spain Pancreatic Adenocarcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Pancreatic Adenocarcinoma Treatment Market, Segmentation By Affected Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Pancreatic Adenocarcinoma Treatment Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Pancreatic Adenocarcinoma Treatment Market

• 21.1. Eastern Europe Pancreatic Adenocarcinoma Treatment Market Overview
• 21.2. Eastern Europe Pancreatic Adenocarcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Pancreatic Adenocarcinoma Treatment Market, Segmentation By Affected Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Pancreatic Adenocarcinoma Treatment Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Pancreatic Adenocarcinoma Treatment Market

• 22.1. Russia Pancreatic Adenocarcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Pancreatic Adenocarcinoma Treatment Market, Segmentation By Affected Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Pancreatic Adenocarcinoma Treatment Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Pancreatic Adenocarcinoma Treatment Market

• 23.1. North America Pancreatic Adenocarcinoma Treatment Market Overview
• 23.2. North America Pancreatic Adenocarcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Pancreatic Adenocarcinoma Treatment Market, Segmentation By Affected Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Pancreatic Adenocarcinoma Treatment Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Pancreatic Adenocarcinoma Treatment Market

• 24.1. USA Pancreatic Adenocarcinoma Treatment Market Overview
• 24.2. USA Pancreatic Adenocarcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Pancreatic Adenocarcinoma Treatment Market, Segmentation By Affected Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Pancreatic Adenocarcinoma Treatment Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Pancreatic Adenocarcinoma Treatment Market

• 25.1. Canada Pancreatic Adenocarcinoma Treatment Market Overview
• 25.2. Canada Pancreatic Adenocarcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Pancreatic Adenocarcinoma Treatment Market, Segmentation By Affected Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Pancreatic Adenocarcinoma Treatment Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Pancreatic Adenocarcinoma Treatment Market

• 26.1. South America Pancreatic Adenocarcinoma Treatment Market Overview
• 26.2. South America Pancreatic Adenocarcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Pancreatic Adenocarcinoma Treatment Market, Segmentation By Affected Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Pancreatic Adenocarcinoma Treatment Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Pancreatic Adenocarcinoma Treatment Market

• 27.1. Brazil Pancreatic Adenocarcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Pancreatic Adenocarcinoma Treatment Market, Segmentation By Affected Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Pancreatic Adenocarcinoma Treatment Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Pancreatic Adenocarcinoma Treatment Market

• 28.1. Middle East Pancreatic Adenocarcinoma Treatment Market Overview
• 28.2. Middle East Pancreatic Adenocarcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Pancreatic Adenocarcinoma Treatment Market, Segmentation By Affected Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Pancreatic Adenocarcinoma Treatment Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Pancreatic Adenocarcinoma Treatment Market

• 29.1. Africa Pancreatic Adenocarcinoma Treatment Market Overview
• 29.2. Africa Pancreatic Adenocarcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Pancreatic Adenocarcinoma Treatment Market, Segmentation By Affected Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Pancreatic Adenocarcinoma Treatment Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Pancreatic Adenocarcinoma Treatment Market Competitive Landscape And Company Profiles

• 30.1. Pancreatic Adenocarcinoma Treatment Market Competitive Landscape
• 30.2. Pancreatic Adenocarcinoma Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sanofi Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Pancreatic Adenocarcinoma Treatment Market Other Major And Innovative Companies

• 31.1. AstraZeneca plc
• 31.2. Novartis AG
• 31.3. GlaxoSmithKline plc
• 31.4. Takeda Pharmaceutical Company Limited (Japan)
• 31.5. Eli Lilly and Company
• 31.6. Amgen Inc.
• 31.7. Teva Pharmaceutical Industries Ltd
• 31.8. Mylan N.V.
• 31.9. Astellas Pharma Inc.
• 31.10. Sun Pharmaceutical Industries Ltd.
• 31.11. Ipsen SA
• 31.12. Clovis Oncology Inc.
• 31.13. Oncolytics Biotech, Inc.
• 31.14. Zydus Cadila
• 31.15. PharmaCyte Biotech Inc.

32. Global Pancreatic Adenocarcinoma Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Pancreatic Adenocarcinoma Treatment Market

34. Recent Developments In The Pancreatic Adenocarcinoma Treatment Market

35. Pancreatic Adenocarcinoma Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Pancreatic Adenocarcinoma Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Pancreatic Adenocarcinoma Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Pancreatic Adenocarcinoma Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer